IGFBP2 may promote the conversion of endothelial cells to mesenchymal cells through TGF-β signaling, thus aggravating cardiac fibrosis progression, which negatively affects the prognoses and left ventricular functions of DCM patients. Here, IGFBP2 is linked to familial dilated cardiomyopathy.